Shulman, L. N., Berry, D. A., Cirrincione, C. T., Becker, H., Perez, E. A., O’Regan, R., … Winer, E. P. (2013). Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Shulman, Lawrence N., Donald A. Berry, Constance T. Cirrincione, Heather Becker, Edith A. Perez, Ruth O’Regan, Silvana Martino, et al. “Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.

Shulman LN, Berry DA, Cirrincione CT, Becker H, Perez EA, O’Regan R, et al. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.

Shulman, Lawrence N., et al. “Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, AMER SOC CLINICAL ONCOLOGY, 2013.

Shulman LN, Berry DA, Cirrincione CT, Becker H, Perez EA, O’Regan R, Martino S, Shapiro CL, Atkins J, Schneider C, Kimmick GG, Burstein HJ, Norton L, Musa HB, Hudis C, Winer EP. Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.